Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial | Zendy

Philippe Armand | Zendy; Ar Nagler | Zendy; Edie Weller | Zendy; Steven M. Devine | Zendy; David Avigan | Zendy; YiBin Chen | Zendy; Mark Kaminski | Zendy; H. Kent Holland | Zendy; Jane N. Winter | Zendy; James R. Mason | Zendy; Joseph W. Fay | Zendy; David A. Rizzieri | Zendy; Chitra Hosing | Zendy; Edward D. Ball | Zendy; Joseph P. Uberti | Zendy; Hillard M. Lazarus | Zendy; Markus Y. Mapara | Zendy; Stephanie A. Gregory | Zendy; John M. Timmerman | Zendy; David Andorsky | Zendy; Reuven Or | Zendy; Edmund K. Waller | Zendy; Rinat RotemYehudar | Zendy; Leo I. Gordon | Zendy

Open Access

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

Author(s) -

Philippe Armand,

Ar Nagler,

Edie Weller,

Steven M. Devine,

David Avigan,

YiBin Chen,

Mark Kaminski,

H. Kent Holland,

Jane N. Winter,

James R. Mason,

Joseph W. Fay,

David A. Rizzieri,

Chitra Hosing,

Edward D. Ball,

Joseph P. Uberti,

Hillard M. Lazarus,

Markus Y. Mapara,

Stephanie A. Gregory,

John M. Timmerman,

David Andorsky,

Reuven Or,

Edmund K. Waller,

Rinat RotemYehudar,

Leo I. Gordon

Publication year - 2013

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.48.3685

Subject(s) - medicine , blockade , hematopoietic stem cell transplantation , oncology , transplantation , immune system , lymphoma , immune checkpoint , immunology , receptor

The Programmed Death-1 (PD-1) immune checkpoint pathway may be usurped by tumors, including diffuse large B-cell lymphoma (DLBCL), to evade immune surveillance. The reconstituting immune landscape after autologous hematopoietic stem-cell transplantation (AHSCT) may be particularly favorable for breaking immune tolerance through PD-1 blockade.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research